U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415330) titled 'Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction' on Jan. 29.
Brief Summary: This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.
Study Star...